Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 7.92%
- Poor long term growth as Net Sales has grown by an annual rate of 11.23% and Operating profit at 5.06% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.86
Flat results in Sep 25
With ROCE of 5.7, it has a Expensive valuation with a 2.8 Enterprise value to Capital Employed
Stock DNA
Commodity Chemicals
INR 37 Cr (Micro Cap)
3,375.00
32
0.00%
1.68
0.19%
6.68
Total Returns (Price + Dividend) 
Caprolactam Chem for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Caprolactam Chemicals Faces Intense Selling Pressure Amid Consecutive Gains
Caprolactam Chemicals Ltd has encountered a rare market phenomenon today, with the stock registering a lower circuit and an exclusive queue of sell orders, signalling extreme selling pressure and distress selling. Despite a strong run of consecutive gains over the past eight days, the stock’s current trading session reveals a stark absence of buyers, raising concerns about market sentiment and potential volatility ahead.
Read More
Caprolactam Chemicals Faces Intense Selling Pressure Amid Lower Circuit Lock
Caprolactam Chemicals Ltd witnessed a sharp decline today as the stock hit its lower circuit, marked by an overwhelming presence of sell orders and an absence of buyers. This extreme selling pressure signals distress among investors, with the stock closing down 5.00% against a marginal 0.30% fall in the Sensex, underscoring the severity of the sell-off in the commodity chemicals sector.
Read More
Caprolactam Chemicals Hits New 52-Week High at Rs.69
Caprolactam Chemicals has reached a significant milestone by touching a new 52-week high of Rs.69, marking a notable phase of momentum for the commodity chemicals company. This achievement reflects a sustained upward trend over the past week, underscoring the stock’s strong performance relative to its sector and broader market indices.
Read More Announcements 
Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 31St December 2025
27-Jan-2026 | Source : BSECaprolactam Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve Unaudited financial results for the Quarter ended 31st December 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
07-Jan-2026 | Source : BSECompliance Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018
Closure of Trading Window
30-Dec-2025 | Source : BSEClosure of Trading Window for the quarter ended December 31 2025
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Siddharth Shankarlal Bhanushali (22.98%)
Aliya Khatun (1.17%)
43.5%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is -7.81% vs 59.01% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is -63.89% vs 180.00% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 73.59% vs -29.53% in Sep 2024
Growth in half year ended Sep 2025 is 313.04% vs -195.83% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'24
YoY Growth in nine months ended Dec 2024 is -7.07% vs -27.56% in Dec 2023
YoY Growth in nine months ended Dec 2024 is -425.00% vs -96.65% in Dec 2023
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is -3.16% vs -29.27% in Mar 2024
YoY Growth in year ended Mar 2025 is -455.00% vs -92.16% in Mar 2024